Research graph
References from Early Adoption and Diffusion of Oral Semaglutide in US Adults With Obesity. Local targets link to admitted publications; unresolved targets remain external evidence.
Once-weekly semaglutide in adults with overweight or obesity.
10.1056/nejmoa2032183 · 2021 · External reference
Oral semaglutide at a dose of 25 mg in adults with overweight or obesity.
10.1056/nejmoa2500969 · 2025 · External reference
Food and Drug Administration’s obesity drug guidance document: a short history.
10.1161/circulationaha.111.028381 · 2012 · External reference
Uptake of and disparities in semaglutide and tirzepatide prescribing for obesity in the US.
10.1001/jama.2025.4735 · 2025 · External reference
Orforglipron: first approval.
10.1007/s40265-026-02363-5 · 2026 · External reference
What to know about the new semaglutide pill for obesity.
10.1001/jama.2026.0035 · 2026 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
